Insight Molecular Diagnostics Inc. Common Stock IMDX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 57%+12.9pp | 44%— | —— | 8.6%-24.6pp | |
| Operating margin | -1,260.8%+1,984pp | -3,245.1%-1,573pp | -1,672.4%+206pp | -1,878.6%-918pp | |
| Net margin | -1,238.5%+1,987pp | -3,225%-1,377pp | -1,848.4%+5,761pp | -7,609.8%-6,780pp | |
| EBITDA margin | -1,206.8%+1,960pp | -3,166.7%-1,600pp | -1,566.5%+153pp | -1,719.1%-813pp | |
| Free cash flow margin | -625.6%+502pp | -1,127.3%— | —— | -5,209.6%-4,715pp | |
| Returns | |||||
| Return on assets | -165.1%-54.8pp | -110.3%-78.6pp | -31.8%+24.4pp | -56.2%+3.5pp | |
| Efficiency | |||||
| Asset turnover | 0.1×+0.1× | 0×0.0× | 0×0.0× | 0×-0.1× | |
| Inventory turnover | 4.1×— | —— | —— | —— | |
| Liquidity | |||||
| Current ratio | 1.3×-0.3× | 1.6×+0.1× | 1.5×-0.6× | 2.1×-0.7× | |
| Quick ratio | 1.2×-0.3× | 1.6×+0.1× | 1.5×-0.6× | 2.1×-0.7× | |
| Cash ratio | 1×-0.2× | 1.2×-0.1× | 1.3×-0.6× | 1.9×-0.7× | |
| Leverage | |||||
| Debt-to-assets | 0.1×0.0× | 0.1×— | —— | 0×— | |
| Per Share | |||||
| Book value per share | -$1.03-9.9% | -$0.94-135% | $2.68-56.8% | $6.19+744% | |
| Valuation | |||||
| Market capitalization | $185.35M+92.3% | —— | —— | —— | |
| Enterprise value | $160.03M+113% | —— | —— | —— | |
| Price / sales | 95.1×+72.5× | —— | —— | —— | |
| EV / sales | 82.1×+64.4× | —— | —— | —— | |
| Free cash flow yield | -14.8%+10.1pp | —— | —— | —— | |
| Earnings yield | -25.8%+40.0pp | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) runs a 51.3% gross margin and a -2500.7% operating margin, with a -2454.6% net margin.
- Where do Insight Molecular Diagnostics Inc. Common Stock's ratios come from?
- Every ratio is computed from Insight Molecular Diagnostics Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
